SAB Biotherapeutics Inc (SABS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.56 (+1.71%), Market cap $0.27B, 52-week low–high $1.69 ~ $4.59.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Financial statements, price targets, institutional (13F) holdings and related news for SAB Biotherapeutics Inc are updated in real time on BlackAll Trade.
SAB Biotherapeutics Inc trades at $3.56 (+1.71%). Real-time quotes and charts are available on BlackAll Trade.
SAB Biotherapeutics Inc has a market cap of about $0.27B.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious dis